Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial

by on 10 de juny de 2025 with No hi ha comentaris
  • Bailón, L., Moltó, J., Curran, A., Cadiñanos, J., de Quirós, J., de los Santos, I.,…Brander, C., Mothe, B., Grp, A.-S. (2025). Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial. Nature Communications, 16(1), Article 2146. https://doi.org/10.1038/s41467-025-57284-w

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *